Straits Times Index
3,084.70 +18.76 (+0.61%) S&P 500
4,568.18 +13.29 (+0.29%) Dow
35,472.60 +55.62 (+0.16%) Nasdaq
14,326.75 +44.99 (+0.32%) Bitcoin USD
37,816.41 +334.15 (+0.89%) CMC Crypto 200
780.82 -4.68 (-0.60%)
Quest Diagnostics Incorporated (DGX)
| Previous close | 135.72 |
| Open | 135.53 |
| Bid | 136.09 x 1100 |
| Ask | 136.23 x 900 |
| Day's range | 135.86 - 136.61 |
| 52-week range | 119.59 - 158.34 |
| Volume | |
| Avg. volume | 907,353 |
| Market cap | 15.322B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | 20.34 |
| EPS (TTM) | 6.70 |
| Earnings date | 31 Jan 2024 - 05 Feb 2024 |
| Forward dividend & yield | 2.84 (2.09%) |
| Ex-dividend date | 16 Jan 2024 |
| 1y target est | 142.64 |
PR NewswireQuest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).
ZacksQuest Diagnostics' (DGX) New Pact to Advance Cancer Screening
Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.
- PR Newswire
Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
Universal DX ("UDX"), a biotech company on a mission to transform cancer into a curable disease, today announced a strategic collaboration with Quest Diagnostics ("Quest") (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve colorectal cancer screening in the United States – for which more than 110 million people may be eligible.i
